Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.
SELLAS Life Sciences is rated Hold, with a $9.25 price target, as the current valuation reflects REGAL trial success ...
Asianet Newsable on MSN
SLS stock slips 3% as pancreatic cancer lab data leave REGAL wait unanswered
SLS investors have been closely watching for two key developments: late-stage REGAL study data for the company’s GPS cancer ...
A test article for NASA’s Space Launch System’s solid rocket booster fired for more than two minutes Thursday on a test stand in Utah. Credit: NASA TV / Spaceflight Now Northrop Grumman ignited a full ...
Mercedes-Benz and AMG have been teasing us with the prospect of an all-electric supercar since the SLS AMG E-Cell concept broke cover in 2010. Now at the Paris Motor Show, Mercedes has presented the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results